IGC Pharma announces CALMA Phase 2 trial expansion

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences in Ontario, Canada. This expansion marks a key milestone in IGC Pharma’s strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and expanding the Company’s clinical footprint. The CALMA trial at HHS will be led by Dr. Alexandra Papaioannou, a distinguished geriatrician and Executive Director of HHS’ Geras Centre for Aging Research, whose expertise in aging, frailty, and dementia will play a critical role in the trial’s success.